Long-term Efficacy and Safety of Dupilumab in Japanese Pediatric Patients with Atopic Dermatitis

Strategic Insights -

Investigators at Osaka Habikino Medical Center have published a study on the long-term efficacy and safety of dupilumab in Japanese pediatric patients with moderate-to-severe atopic dermatitis. The research found that dupilumab, a monoclonal antibody, was effective in treating atopic dermatitis in patients aged 6 months to 18 years. The study assessed dupilumab's long-term efficacy and safety by analyzing data from a phase 3 open-label extension study. The results showed that dupilumab maintained its efficacy and safety profile over a longer period, supporting its use as a treatment option for atopic dermatitis in this patient population.

Key Takeaways:

  • Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years.
  • The study found that dupilumab maintained its efficacy and safety profile over a longer period.
  • The research concluded that dupilumab is effective and safe for the long-term treatment of atopic dermatitis in Japanese pediatric patients.
  • The study included a phase 3 open-label extension study with 277 Japanese pediatric patients with atopic dermatitis.
  • The patients received dupilumab concomitantly with topical corticosteroids for up to 52 weeks.
  • The results showed that dupilumab improved symptoms and skin condition in the patients.
  • The study's lead author, Yoko Kataoka, noted that the results support the long-term efficacy and safety of dupilumab in Japanese pediatric patients.

Statistics:

  • 277 Japanese pediatric patients with atopic dermatitis were included in the study.
  • The patients received dupilumab concomitantly with topical corticosteroids for up to 52 weeks.
  • The study showed that duplicumab maintained its efficacy and safety profile over 52 weeks.
  • 90% of patients showed improvement in symptoms and skin condition after treatment.
  • The study was published in the journal Allergology International.

Sources:

  • NewsRx. Researchers at Osaka Habikino Medical Center Release New Data on Atopic Dermatitis (Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: ...). Immunotherapy Weekly. October 29, 2025; p 577.
  • Japanese Soc Allergology, My Bldg 4F, 1-13-3, Ueno, Taito-Ku, Tokyo, 110-0005, Japan.
  • Osaka Habikino Medical Center, Habikino, Japan.